tiprankstipranks
BioNTech SE (MX:BNTXN)
:BNTXN
Mexico Market
BNTXN
BioNTech SE
RESEARCH TOOLSreports

BioNTech SE (BNTXN) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

BNTXN Analyst Ratings

Strong Buy
12Ratings
Strong Buy
9 Buy
3 Hold
0 Sell
Based on 12 analysts giving stock ratings to
BioNTech
SE
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BNTXN Stock 12 Month Forecast

Average Price Target

$2,191.18
▲(37.81% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $2,191.18 with a high forecast of $2,758.62 and a low forecast of $1,641.20. The average price target represents a 37.81% change from the last price of $1,590.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1589":"$1,589","2174":"$2,174","2759":"$2,759","1881.5":"$1,881.5","2466.5":"$2,466.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2758.62068996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.76K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2191.18288981,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1641.20471428,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.64K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1589,1881.5,2174,2466.5,2759],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1590,1679.8938992276924,1769.7877984553847,1859.681697683077,1949.5755969107693,2039.4694961384616,2129.363395366154,2219.2572945938464,2309.1511938215385,2399.0450930492307,2488.9389922769233,2578.8328915046154,2668.7267907323076,{"y":2758.62068996,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1590,1636.2448376776922,1682.4896753553846,1728.7345130330768,1774.9793507107693,1821.2241883884615,1867.4690260661537,1913.713863743846,1959.9587014215383,2006.2035390992305,2052.448376776923,2098.6932144546154,2144.9380521323073,{"y":2191.18288981,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1590,1593.9388241753845,1597.8776483507693,1601.8164725261538,1605.7552967015386,1609.694120876923,1613.6329450523076,1617.5717692276924,1621.5105934030769,1625.4494175784614,1629.3882417538462,1633.3270659292307,1637.2658901046154,{"y":1641.20471428,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2000,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2050,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1871.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1879,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1950,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1800,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1645,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1999,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1866.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1600.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1735,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1633,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1590,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2,759Average Price Target$2,191Lowest Price Target$1,641
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on MX:BNTXN
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$2,444.35
Buy
53.73%
Upside
Reiterated
07/24/26
Wells Fargo Reaffirms Their Buy Rating on BioNTech SE (BNTX)
BMO Capital Analyst forecast on MX:BNTXN
Evan Seigerman
BMO Capital
BMO Capital
$2,234.83
Buy
40.56%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (Other OTC: PMCUF) and BioNTech SE (NASDAQ: BNTX)
Morgan Stanley Analyst forecast on MX:BNTXN
Terence Flynn
Morgan Stanley
Morgan Stanley
$2,199.91→$2,077.7
Buy
30.67%
Upside
Reiterated
07/08/26
BioNTech price target lowered to $119 from $126 at Morgan StanleyBioNTech price target lowered to $119 from $126 at Morgan Stanley
Bernstein Analyst forecast on MX:BNTXN
Jeffrey Walch
Bernstein
Bernstein
$1,676.12
Hold
5.42%
Upside
Reiterated
06/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Dexcom (NASDAQ: DXCM), Fractyl Health, Inc. (NASDAQ: GUTS) and BioNTech SE (NASDAQ: BNTX)
Jefferies Analyst forecast on MX:BNTXN
Akash Tewari
Jefferies
Jefferies
$2,409.43
Buy
51.54%
Upside
Reiterated
06/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)
Bank of America Securities Analyst forecast on MX:BNTXN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2,269.75→$2,182.45
Buy
37.26%
Upside
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: MannKind (NASDAQ: MNKD), BioNTech SE (NASDAQ: BNTX) and Pfizer (NYSE: PFE)
Canaccord Genuity Analyst forecast on MX:BNTXN
John Newman
Canaccord Genuity
Canaccord Genuity
$2,758.62
Buy
73.50%
Upside
Reiterated
06/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on MX:BNTXN
David Dai
UBS
UBS
$2,042.78→$2,357.05
Buy
48.24%
Upside
Upgraded
05/27/26
BioNTech upgraded to Buy from Neutral at UBSBioNTech upgraded to Buy from Neutral at UBS
J.P. Morgan Analyst forecast on MX:BNTXN
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$1,745.96
Hold
9.81%
Upside
Reiterated
05/20/26
J.P. Morgan Keeps Their Hold Rating on BioNTech SE (BNTX)
Berenberg Bank Analyst forecast on MX:BNTXN
Harry Gillis
Berenberg Bank
Berenberg Bank
$2,706.24→$2,444.35
Buy
53.73%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Siemens Healthineers AG (Other OTC: SEMHF) and BioNTech SE (NASDAQ: BNTX)
TD Cowen Analyst forecast on MX:BNTXN
Yaron Werber
TD Cowen
TD Cowen
$1,641.2
Hold
3.22%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)
Goldman Sachs Analyst forecast on MX:BNTXN
Asad Haider
Goldman Sachs
Goldman Sachs
$2,304.67→$2,322.13
Buy
46.05%
Upside
Reiterated
05/05/26
BioNTech SE (BNTX) Receives a Buy from Goldman Sachs
H.C. Wainwright Analyst forecast on MX:BNTXN
Robert Burns
H.C. Wainwright
H.C. Wainwright
$2,269.75
Buy
42.75%
Upside
Reiterated
04/27/26
Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline
Deutsche Bank Analyst forecast on MX:BNTXN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$2,444.35
Buy
53.73%
Upside
Reiterated
03/17/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Truist Financial Analyst forecast on MX:BNTXN
Asthika Goonewardene
Truist Financial
Truist Financial
$2,706.24
Buy
70.20%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), BioNTech SE (NASDAQ: BNTX) and Skye Bioscience (NASDAQ: SKYE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on MX:BNTXN
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
$2,444.35
Buy
53.73%
Upside
Reiterated
07/24/26
Wells Fargo Reaffirms Their Buy Rating on BioNTech SE (BNTX)
BMO Capital Analyst forecast on MX:BNTXN
Evan Seigerman
BMO Capital
BMO Capital
$2,234.83
Buy
40.56%
Upside
Reiterated
07/13/26
Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (Other OTC: PMCUF) and BioNTech SE (NASDAQ: BNTX)
Morgan Stanley Analyst forecast on MX:BNTXN
Terence Flynn
Morgan Stanley
Morgan Stanley
$2,199.91→$2,077.7
Buy
30.67%
Upside
Reiterated
07/08/26
BioNTech price target lowered to $119 from $126 at Morgan StanleyBioNTech price target lowered to $119 from $126 at Morgan Stanley
Bernstein Analyst forecast on MX:BNTXN
Jeffrey Walch
Bernstein
Bernstein
$1,676.12
Hold
5.42%
Upside
Reiterated
06/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Dexcom (NASDAQ: DXCM), Fractyl Health, Inc. (NASDAQ: GUTS) and BioNTech SE (NASDAQ: BNTX)
Jefferies Analyst forecast on MX:BNTXN
Akash Tewari
Jefferies
Jefferies
$2,409.43
Buy
51.54%
Upside
Reiterated
06/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)
Bank of America Securities Analyst forecast on MX:BNTXN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$2,269.75→$2,182.45
Buy
37.26%
Upside
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: MannKind (NASDAQ: MNKD), BioNTech SE (NASDAQ: BNTX) and Pfizer (NYSE: PFE)
Canaccord Genuity Analyst forecast on MX:BNTXN
John Newman
Canaccord Genuity
Canaccord Genuity
$2,758.62
Buy
73.50%
Upside
Reiterated
06/01/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on MX:BNTXN
David Dai
UBS
UBS
$2,042.78→$2,357.05
Buy
48.24%
Upside
Upgraded
05/27/26
BioNTech upgraded to Buy from Neutral at UBSBioNTech upgraded to Buy from Neutral at UBS
J.P. Morgan Analyst forecast on MX:BNTXN
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$1,745.96
Hold
9.81%
Upside
Reiterated
05/20/26
J.P. Morgan Keeps Their Hold Rating on BioNTech SE (BNTX)
Berenberg Bank Analyst forecast on MX:BNTXN
Harry Gillis
Berenberg Bank
Berenberg Bank
$2,706.24→$2,444.35
Buy
53.73%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Siemens Healthineers AG (Other OTC: SEMHF) and BioNTech SE (NASDAQ: BNTX)
TD Cowen Analyst forecast on MX:BNTXN
Yaron Werber
TD Cowen
TD Cowen
$1,641.2
Hold
3.22%
Upside
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Orthofix Medical (NASDAQ: OFIX), BioNTech SE (NASDAQ: BNTX) and Cogent Biosciences (NASDAQ: COGT)
Goldman Sachs Analyst forecast on MX:BNTXN
Asad Haider
Goldman Sachs
Goldman Sachs
$2,304.67→$2,322.13
Buy
46.05%
Upside
Reiterated
05/05/26
BioNTech SE (BNTX) Receives a Buy from Goldman Sachs
H.C. Wainwright Analyst forecast on MX:BNTXN
Robert Burns
H.C. Wainwright
H.C. Wainwright
$2,269.75
Buy
42.75%
Upside
Reiterated
04/27/26
Analyst Reiterates Buy on BioNTech, Maintains $130 Price Target on Strength of Pumitamig Oncology Pipeline
Deutsche Bank Analyst forecast on MX:BNTXN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$2,444.35
Buy
53.73%
Upside
Reiterated
03/17/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Truist Financial Analyst forecast on MX:BNTXN
Asthika Goonewardene
Truist Financial
Truist Financial
$2,706.24
Buy
70.20%
Upside
Reiterated
03/13/26
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), BioNTech SE (NASDAQ: BNTX) and Skye Bioscience (NASDAQ: SKYE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

3 Months
John NewmanCanaccord Genuity
Success Rate
8/13 ratings generated profit
62%
Average Return
+5.35%
Copying John Newman's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +5.35% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
12/24 ratings generated profit
50%
Average Return
+0.77%
Copying Robert Burns's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.77% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
10/24 ratings generated profit
42%
Average Return
-4.88%
Copying Robert Burns's trades and holding each position for 2 Years would result in 41.67% of your transactions generating a profit, with an average return of -4.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTXN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
7
9
14
9
8
Buy
20
16
19
12
10
Hold
2
3
5
6
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
28
38
27
23
In the current month, BNTXN has received 18 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. BNTXN average Analyst price target in the past 3 months is 2,191.18.
Each month's total comprises the sum of three months' worth of ratings.

BNTXN Financial Forecast

BNTXN Earnings Forecast

Next quarter’s earnings estimate for BNTXN is -$42.05 with a range of -$61.72 to -$26.62. The previous quarter’s EPS was -$42.03. BNTXN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.76% of the time in the same period. In the last calendar year BNTXN has Performed in-line its overall industry.
Next quarter’s earnings estimate for BNTXN is -$42.05 with a range of -$61.72 to -$26.62. The previous quarter’s EPS was -$42.03. BNTXN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.76% of the time in the same period. In the last calendar year BNTXN has Performed in-line its overall industry.

BNTXN Sales Forecast

Next quarter’s sales forecast for BNTXN is $3.22B with a range of $1.98B to $4.31B. The previous quarter’s sales results were $2.40B. BNTXN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.16% of the time in the same period. In the last calendar year BNTXN has Performed in-line its overall industry.
Next quarter’s sales forecast for BNTXN is $3.22B with a range of $1.98B to $4.31B. The previous quarter’s sales results were $2.40B. BNTXN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.16% of the time in the same period. In the last calendar year BNTXN has Performed in-line its overall industry.

BNTXN Stock Forecast FAQ

What is MX:BNTXN’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is 2,191.18.
    What is MX:BNTXN’s upside potential, based on the analysts’ average price target?
    BioNTech SE has 37.81% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BioNTech SE a Buy, Sell or Hold?
          BioNTech SE has a consensus rating of Strong Buy, which is based on 9 buy ratings, 3 hold ratings and 0 sell ratings.
            What is BioNTech SE’s share price target?
            The average share price target for BioNTech SE is 2,191.18. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $2,758.62 ,and the lowest forecast is $1,641.20. The average share price target represents 37.81% Increase from the current price of $1,590.
              What do analysts say about BioNTech SE?
              BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of BioNTech SE?
                To buy shares of MX:BNTXN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.